about
The ANG-(1-7)/ACE2/mas axis in the regulation of nephron functionManagement of non-alcoholic fatty liver disease in 2015Endocrine causes of nonalcoholic fatty liver diseaseTowards a system level understanding of non-model organisms sampled from the environment: a network biology approachAngiotensin II protects primary rat hepatocytes against bile salt-induced apoptosisTranslation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNARegulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis.Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.Involvement of glomerular renin-angiotensin system (RAS) activation in the development and progression of glomerular injury.Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C CoinfectionAngiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosisAngiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research.Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitisLiver disease and the renin-angiotensin system: recent discoveries and clinical implications.Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis.Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2.The renin-angiotensin system and diabetes: an update.Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients.Renin-angiotensin system in the pathogenesis of liver fibrosis.Effect of angiotensin-converting enzyme inhibitor, lisinopril on morphological and biochemical aspects of fibrotic liver regeneration.Overview: Liver disease and transplantation.Liver disease in the patient with Fontan circulation.Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.Hepatocytes in liver injury: Victim, bystander, or accomplice in progressive fibrosis?Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease.Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.Renin angiotensin system in liver diseases: Friend or foe?Effects of Yinchenhao decoction on self-regulation of renin-angiotensin system by targeting angiotensin converting enzyme 2 in bile duct-ligated rat liver.Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B.Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.Angiotensin II increases mRNA levels of all TGF-beta isoforms in quiescent and activated rat hepatic stellate cells.Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation.Reversal of liver fibrosis.Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling.Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat.β-Amino acid substitution to investigate the recognition of angiotensin II (AngII) by angiotensin converting enzyme 2 (ACE2).Pharmacologic inhibition of the renin-angiotensin system did not attenuate hepatic toxicity induced by carbon tetrachloride in rats.The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).
P2860
Q24633556-37790517-FD36-4754-9C3A-CEC33788E32FQ26771148-49014422-9A58-4A31-9456-441749939AD8Q26780254-4CFA1D7D-3834-4BCE-A45E-BD67C77EE774Q28476698-AAFEB160-0226-4F46-BDB6-69F8852D956DQ28484552-81F39FBC-BB1F-40CD-86FF-3FAB01BEA594Q33652543-A8178F6F-63D5-4FA3-A8B8-E9FDA2D92445Q35217354-1AC3E9FC-90C7-4388-ADAF-0EDFD562217EQ35744613-AC338F4F-9F07-4617-B34E-82C93DAACB78Q35895028-0438D70C-2C5E-4235-985A-839F5A0BA0CAQ36410515-5089B5E1-ED95-4FE8-B5A6-E904669389AAQ36808001-397E185A-2D9C-41A0-9E8E-BE378EF4E5E4Q37120331-D9CBAAE4-4373-4C0B-805D-AA31625C5680Q37122480-2CEAF417-EEB4-4969-9287-27EF9F670472Q37192537-89D53C3A-98E8-4D49-8021-713B555C059AQ37203406-AD71F0F3-76C1-4CC5-AABB-296698662FECQ37264506-45E7E729-1767-4AA8-93C1-C4B413E76752Q37344441-B60E9E26-C91F-4364-9C17-00C0F7AA93CBQ37413270-72E99DCF-7369-4D93-9FDD-03486E73EB9EQ37507825-7672E2EA-4B01-4CCF-8A87-BE53B4AF6BBFQ37532238-B0471EF0-3317-4EF6-B68B-AEAFB60089B4Q37607379-B80754AE-7929-4B7F-B162-0DD8F1F735F5Q37858605-BF8D5239-572D-47C8-B582-E0F990153FBEQ38212215-FFA5DFD1-505E-474E-BD38-05D3ECE7C84AQ38560320-17D3B5C2-C7A2-4EC5-BA04-C90586E60A29Q38782387-A5E1D220-FAF8-4069-BD35-57CF45367316Q38895037-E281E727-A900-40D6-9B5A-7B85D92EB7DAQ39360840-061AB6F7-8DFA-4840-A6BF-86A5515D718AQ40680622-A7D8444E-C350-44A5-92EB-42218835DDE3Q42695116-26C539C5-070B-4174-BC16-8F32397909A1Q42972424-C83D5CAF-EAAA-4811-9497-9BE17E0A95EEQ43015011-CF854CD7-E23E-4EAD-A0F4-0A5A328095C7Q43037191-C90E62DC-8D90-4826-BE4C-94DD247E2564Q43104809-985B4640-B60D-41EE-A3ED-975F85D27C21Q44817032-FBB2EA5C-EDAC-4F1F-80A3-3C2ADCE9B885Q45255856-46751C4A-57F6-42A0-9C4E-1D30E1E7D5D7Q45918584-29F1B919-75F0-480D-B0D6-1F9F7CF80074Q46398072-F284CF4A-9351-497B-A7E0-367FC276777BQ47851502-16F85ABA-DB0A-4DBF-9F82-F62D1708FFD5
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Liver fibrosis: a balance of ACEs?
@en
type
label
Liver fibrosis: a balance of ACEs?
@en
prefLabel
Liver fibrosis: a balance of ACEs?
@en
P2093
P356
P1433
P1476
Liver fibrosis: a balance of ACEs?
@en
P2093
Fiona J Warner
Geoffrey W McCaughan
John S Lubel
Peter W Angus
P304
P356
10.1042/CS20070026
P407
P577
2007-08-01T00:00:00Z